EUCTR2004-004848-45-AT进行中（未招募）不适用
HCV/HIV Coinfection- STUDY: MULTICENTER STUDY TO EVALUATE THE EFFICACY OF 48 WEEKS COMBINATION-THERAPY WITH PEGYLATED INTERFERON ALFA 2A (PEG-IFN ALFA 2A) AND DIFFERENT DOSES OF RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C AND HIV -COINFECTION - HIVCopeg
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male and female patients with chronic hepatitis C and HIV coinfection
- •-Age between 18 and 65 years
- •-Positive HCV-RNA level in serum (determined with quantitative PCR (COBAS AMPLICOR? MONITOR HCV test v 2.0)
- •-Serologic evidence of HIV infection by HIV-1 antibody or detection of HIV-1 RNA
- •-Patients with CD4 cell count > 100/µl
- •-Patients with CD4 cell count between 100 and 200/µl have to be on HAART therapy for 6 months before study start
- •-Patients with CD4 cell count > 200/µl can be on HAART therapy
- •-HAART should not include Zidovudin and Didanosin
- •-Laboratory parameters (within 35 days prior to study start):
- •- Hemoglobin values > 11 g/dl in women or > 12 g/dl in men
- •- Leukocyte count (WBC) > 3 000 /µl
- •- Platelets count > 50 000/µl
- •-Creatinine not 1.5 times higher than normal
- •- normal TSH
- •-Laboratory parameters (within 3 months prior to study start):
- •- Hepatitis A anti – IgM negativity
- •-HbsAg negativity
- •-Negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug
- •-All fertile males and females receiving ribavirin must be using two different forms of effective contraception during treatment and during the 6 months after treatment end
- •-Written informed consent obtained
- •-A liver biopsy within 6 months prior to study start
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Class B or C cirrhosis as coded by Child Pugh classification (Appendix A) if the result of a liver biopsy is available
- •-Women with ongoing pregnancy or breast feeding
- •-Therapy with any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) 6 months prior to the first dose of study drug
- •-Any investigational drug 6 weeks prior to the first dose of study drug
- •-Active drug abuse (including alcohol dependence) within 6 months prior to study start.
- •-Diabetes mellitus in patients receiving an insulin therapy
- •-History or other evidence of a medical condition associated with chronic liver disease other than HCV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures)
- •-Active HIV-related opportunistic infection and/or malignancy requiring acute systemic therapy
- •-History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease within the last 6 months
- •-History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer attherapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time or any history of the following: a suicidal attempt, hospitalization (for other reason than drug abuse) for psychiatric disease, or a period of disability due to a psychiatric disease. Exception: if there is a current psychiatric report which certifies there is no contraindication to interferon therapy, patient may be included
- •-History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis etc.)
- •-History or other evidence of chronic pulmonary disease associated with functional limitation
- •-History of a severe seizure disorder
- •-History of severe cardiac disease and severe coronary heart disease within the last 6 months (angina pectoris, congestive heart failure, recent myocardial infarction, severe hypertension or sygnificant arrythmia). If there is clinical suspicion of coronary heart disease cardiologic workup of the patient prior to study entry is recommended.
- •-History of thyroid disease poorly controlled on prescribed medications, elevated thyroid stimulating hormone (TSH) concentrations with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease
- •-History or other evidence of severe illness, malignancy or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
- •-History of major organ transplantation with an existing functional graft
- •-Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration)
- •-Inability or unwillingness to provide informed consent or abide by the requirements of the study
- •Additional exclusion criteria concerning ribavirin:
- •-Male partners of women who are pregnant
- •-Any patient with an increased baseline risk for anemia (e.g. thalassemia, spherocytosis, history of GI bleeding, etc) or for whom anemia would be medically problematic
- •-Patients with documented or presumed coronary artery disease or cerebrovascular disease should not be enrolled if, in the judgment of the investigator, an acute decrease in hemoglobin by up to 4 g/dL would not be well-tolerated
研究者
相似试验
已完成
不适用
Prospective cohort study of HCV infection and the risk of developement of maligant lymphomahematopoietic malignancyJPRN-UMIN000003652Clinical Hematology Study Group of National Hospital Organization(CHSG-NHO)2,000
已完成
2 期
Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infectionHIVLiver FibrosisHepatitis CNCT01231685McGill University Health Centre/Research Institute of the McGill University Health Centre9
已完成
4 期
Treatment of Acute Hepatitis C Virus in HIV Co-InfectionHuman Immunodeficiency VirusHepatitis CHIV InfectionsNCT00845676University of California, San Francisco21
Unknown
4 期
Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCVChronic Hepatitis CCo-Infection HIV-HCVNCT00611819University of Valencia59
已完成
不适用
HCV Viral Hepatitis, Blood Sugar Level and Systolic Blood Pressure in EgyptHepatitis C, AcuteHypertensionDiabetesNCT03839979Cairo University71,975